Cytolytic Vaginosis and Bacterial Vaginosis Diagnosis and Treatment

Microbiological Differences

Bacterial Vaginosis (BV) is characterized by replacement of normal H₂O₂-producing Lactobacillus species with high concentrations of anaerobic bacteria, Gardnerella vaginalis, and Mycoplasma hominis, according to the Centers for Disease Control and Prevention (CDC) 1, 2

The American College of Obstetricians and Gynecologists (ACOG) recommends diagnosing BV using clinical criteria (Amsel criteria) requiring three of the following: homogeneous, white, non-inflammatory discharge that smoothly coats vaginal walls, presence of clue cells on microscopic examination, vaginal fluid pH greater than 4.5, and fishy odor of vaginal discharge before or after addition of 10% KOH (whiff test) 1, 2, 3, 4, 5

The CDC reports that BV is the most prevalent cause of vaginal discharge and malodor, with up to 50% of women with BV being asymptomatic 1, 2, 5
BV is characterized by a fishy odor and is not typically associated with significant vulvar irritation, according to the CDC 1, 3, 4

The CDC recommends treating BV with antibiotics such as metronidazole (500 mg orally twice daily for 7 days) or clindamycin, with a high recurrence rate (50-80% within a year) 1, 3, 6
The CDC also states that treatment of male sexual partners is not beneficial in preventing recurrence of BV 1, 3

BV is associated with increased risk for PID, preterm birth, and increased susceptibility to STIs, according to the CDC 1

Probiotics can significantly improve the cure rate in adult bacterial vaginosis (BV) patients, with a risk ratio of 1.53 (95% CI 1.19-1.97) when used as a complementary therapy with antibiotics 7, 8
Meta-analyses show that probiotic supplementation significantly improves BV cure rates compared to standard treatments alone 8, 9
The combination of metronidazole with probiotics shows particularly promising results for microbiological cure (OR 0.09, 95% CI 0.03 to 0.26) 10, 11
Probiotic/estriol preparations have also demonstrated efficacy for symptom resolution (OR 0.04, 95% CI 0.00 to 0.56) 11

While promising, the evidence for probiotics has some limitations, including heterogeneity in study designs, strains used, and dosing protocols 10, 11
There is a need for larger, well-designed randomized controlled trials with standardized methodologies 11